LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Kodu・Aktsiate loetelu・Organon & Co

Search

Organon & Co

Suletud

SektorTervishoid

13.4 0.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.29

Max

13.43

Põhinäitajad
By Trading Economics
Sissetulek	351M 146M
Müük	-47M 1.5B
P/E Sektori keskmine	14.106 49.8
Aktsiakasum	0.71
Dividenditootlus	0.6
Kasumimarginaal	10
Töötajad	10,000
EBITDA	286M 351M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	-15.54% downside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.60% 2.25%
Järgmine tulemuste avaldamine	4. aug 2026
Järgmine dividendimakse kuupäev	11. juuni 2026
Järgmine aktsia dividendi kuupäev (ex-date)	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	26M 3.5B
Eelmine avamishind	12.57
Eelmine sulgemishind	13.4

Uudiste sentiment

By Acuity

69%

31%

317 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

8.53 / 9.18 Toetus ja vastupanu

Organon & Co Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2026, 06:09 UTC

Omandamised, ülevõtmised, äriostud

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27. apr 2026, 02:33 UTC

Omandamised, ülevõtmised, äriostud

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27. apr 2026, 01:04 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7. nov 2025, 14:41 UTC

Omandamised, ülevõtmised, äriostud

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27. apr 2026, 18:07 UTC

Omandamised, ülevõtmised, äriostud

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27. apr 2026, 15:14 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27. apr 2026, 14:56 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27. apr 2026, 13:58 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27. apr 2026, 13:38 UTC

Kuumad aktsiad

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27. apr 2026, 12:18 UTC

Omandamised, ülevõtmised, äriostud

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27. apr 2026, 09:22 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27. apr 2026, 00:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27. apr 2026, 00:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 14:39 UTC

Omandamised, ülevõtmised, äriostud

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 14:01 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 09:23 UTC

Kuumad aktsiad

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Võrdlus sarnastega

Hinnamuutus

Organon & Co Prognoos

Hinnasiht

By TipRanks

-15.54% langus

12 kuu keskmine prognoos

Keskmine 11.2 USD -15.54%

Kõrge 14 USD

Madal 8 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Organon & Co 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

7 ratings

0

Osta

4

Hoia

3

Müü

Põhineb 7 analüütiku instrumendi Organon & Co aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.53 / 9.18Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

There are no events.

Sentiment

By Acuity

317 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

986

JNJ

Johnson and Johnson

224.47

ABBV

AbbVie Inc

204.99

UNH

UnitedHealth Group Inc

366.96

AZN

AstraZeneca PLC

184.44

Live chat